Financial Data and Key Metrics Changes - Fourth quarter revenue reached a record $25.2 million, representing an 18% quarter-over-quarter improvement and a 137% year-over-year increase [8][18] - Full year 2025 revenue totaled $73 million, which is three times higher than the 2024 level [8][18] - Gross margin improved to 24% in Q4, a 9 percentage point increase quarter-over-quarter and a 45 percentage point increase year-over-year [8][18] - Full year gross margin was 11%, a significant improvement from -76% in 2024 [9][18] - Adjusted EBITDA for Q4 was $1.8 million, compared to -$1.4 million in the prior quarter [21] Business Line Data and Key Metrics Changes - The company transitioned all legacy SiMaxx Generation One customers to the Generation Two SiCore platform, with SiMaxx revenue expected to fall to 0% by the end of 2026, down from about 25% at the beginning of the year [92] - The SiCore silicon anode batteries gained broad adoption, particularly in unmanned aerial vehicles (UAVs) [5][6] Market Data and Key Metrics Changes - The company serves five principal end markets: UAVs, satellites and space, light electric vehicles, robotics, and electric vertical takeoff and landing (eVTOL) aircraft [10][12] - The UAV market includes drones used for defense, public safety, security, and logistics, with over 1,500 emergency departments in the U.S. operating drone as first responder programs [11] Company Strategy and Development Direction - The company aims to broaden its product portfolio to unlock new market opportunities and convert customer engagements into formal qualifications and deployments [30] - The focus remains on delivering next-generation silicon anode performance that raises the bar for energy density and sustained power without compromising safety or reliability [30] - The company is strategically investing in diversifying its supply chain and expanding manufacturing capacity within its Fremont facility [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the opportunities ahead, particularly in the context of NDAA compliance and the growing demand for U.S.-manufactured batteries [30][31] - The company anticipates delivering at least $125 million in revenue for 2026, with a goal of achieving positive adjusted EBITDA of at least $4 million [24][25] - The company is positioned to leverage existing relationships and deliver additional upside as market conditions evolve [25] Other Important Information - The company completed its At-the-Market financing facility during Q4 and fully exited its Colorado facility, settling related obligations [8][18] - The company has expanded its battery component sourcing to 11 out of 11 compliant suppliers, ensuring all internal components are sourced from NDAA-compliant countries [7][8] Q&A Session Summary Question: What are the milestones for NDAA compliance in 2026? - Management confirmed that the technical selection of components is complete, and the focus is now on operationalizing agreements with suppliers to meet customer demands [36][38] Question: How many new customers were added in the quarter? - Management indicated that over 100 new customers were added, with many still in the early design phase [47][48] Question: What is the impact of recent geopolitical events on demand? - Management noted an increased urgency from military customers for battery supplies, indicating a pull for products due to current geopolitical tensions [57][59] Question: How does the company view its market share in the drone sector? - Management stated that the current market share is in the single digits, with a focus on high-energy draw drones used for complex missions [77][80] Question: What is the outlook for revenue guidance? - Management confirmed that the current capacity can meet the guidance, with potential upside from additional U.S. drone production not fully baked into the estimates [82][84]

Financial Performance and Key Metrics - The company reported record revenue of $1.43 billion for Q1 2026, a 33% increase year-over-year, marking the highest revenue in its history [7][25] - Adjusted gross margin was 44.7%, exceeding expectations and reflecting improved profitability [7][22] - Adjusted earnings per share (EPS) reached $1.35, more than double the EPS from Q1 of the previous year [7][27] Business Line Performance - Optical revenue increased over 40% year-over-year, driven by strong demand for Waveserver and RLS product lines, each up over 80% [25] - The company experienced significant order activity, leading to a backlog increase of approximately $2 billion, totaling around $7 billion at the end of Q1 [26][54] Market Performance - Orders in India rose by 40% year-over-year, indicating strong demand for managed optical fiber networks (MOFN) in that region [10] - The company noted that nearly all new orders will be fulfilled in fiscal 2027, providing confidence in future revenue growth [26] Company Strategy and Industry Competition - The company aims to strengthen its leadership in high-speed WAN connectivity and expand its addressable market in and around data centers, particularly driven by AI workloads [11][12] - The competitive landscape is evolving, with the company focusing on maintaining market share while balancing pricing strategies [78][82] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the durability of demand and the ability to drive growth through 2027 and beyond, citing strong customer relationships and market dynamics [7][19] - The company anticipates continued strong demand across service providers, hyperscalers, and neoscalers, with expectations for revenue growth to range between $5.9 billion and $6.3 billion for fiscal 2026 [29] Other Important Information - The company is navigating supply chain challenges but is actively working to expand manufacturing capacity and secure component supply [24][25] - Capital expenditures for Q1 were $74 million, significantly higher than the average over the past 12 quarters, reflecting investments to meet growing demand [23] Q&A Session Summary Question: Insights on gross margin performance and pricing dynamics - Management highlighted strong gross margin performance driven by increased capacity demands and engineering cost reductions, with expectations for further improvements in the second half of the year [33][35] Question: Pluggables market outlook - The company is positioned to lead in the 800G pluggables market, with significant growth anticipated as they ramp up production [36][37] Question: Backlog and revenue breakdown - Approximately 80% of the $7 billion backlog consists of products and software, with MOFN contributing significantly to service provider revenue growth [41][44] Question: CapEx spending duration and cost reduction strategies - Management indicated that the current CapEx investments are aimed at setting up for 2027, with ongoing efforts to optimize costs through engineering and supply chain strategies [66][68] Question: Competitive landscape and pricing strategies - The company is balancing pricing strategies with market share considerations, with ongoing discussions about potential price increases as demand remains strong [76][79]

Financial Data and Key Metrics Changes - Fourth quarter sales were essentially flat year-over-year, but excluding the impact from exiting low-margin products, sales would have increased by 3% [4][16] - Adjusted operating margins expanded by 230 basis points, and adjusted EPS improved by 63% year-over-year [5][16] - Full year 2025 net sales were $825.7 million, down 1.3% year-over-year, but excluding the impact from idling facilities, sales decreased only 0.6% [17][18] - Free cash flow improved by 23% to $67.2 million, and net debt was reduced by $44.2 million, resulting in a net leverage ratio of 2.4 [7][18] Business Line Data and Key Metrics Changes - Material Handling net sales decreased by $0.4 million, but excluding the impact of idling facilities, sales increased by 3.4% [17] - Adjusted EBITDA margin for Material Handling was 25.6%, expanding by 290 basis points due to transformation savings [17] - Distribution net sales increased by 0.9%, with adjusted EBITDA margin improving by 160 basis points [17] Market Data and Key Metrics Changes - Growth in industrial and infrastructure markets was offset by lower consumer and vehicle demand [5][18] - The current backlog for matting products is the largest in the history of this business, indicating strong growth potential in infrastructure [22] Company Strategy and Development Direction - The company is focusing on a transformation program aimed at improving profitability and operational efficiency, with a goal of delivering consistent and reliable results [8][11] - Three strategic priorities for 2026 include focusing on core markets, instilling operational excellence, and maximizing profitable growth through disciplined capital allocation [12][14] - The decision to sell Myers Tire Supply is part of a strategy to streamline operations and focus on high-margin growth platforms [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging demand environment and achieve long-term strategic goals [6][7] - The outlook for 2026 includes moderate growth in industrial markets, strong growth in infrastructure, and stable demand in the vehicle market [22][23] - Management is cautious about geopolitical conditions and their potential impact on demand trends [21] Other Important Information - The company returned $23 million to shareholders in 2025 through dividends and share repurchases, emphasizing the importance of shareholder value creation [19][20] - The capital allocation framework balances growth investments with returning cash to shareholders, with plans to increase CapEx to approximately 3% of sales in 2026 [19] Q&A Session Summary Question: Broader end market sentiment and breakdown of industrial subcategories - Management noted that industrial production has been strong, and specific product lines like Akro-Mils and Buckhorn are tracking closely with this strength [28][30] Question: Demand from defense products and military sales - Management confirmed sales to both U.S. military and NATO customers, with expectations for growth driven by geopolitical factors [33][35] Question: Material handling margins and sustainability of new levels - Management indicated that the strong performance in material handling margins is supported by focused transformation efforts and continuous improvement initiatives [38][40] Question: Incremental cost reductions for 2026 - Management acknowledged that some cost savings will carry into 2026, but specific targets are not yet defined due to pending business changes [43][44]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking the first full reporting period post-acquisition [16] - Operating expenses in Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure due to the Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis as it transitions to a bundled add-on reimbursement model starting July 1, 2026 [6] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company aims to achieve a target synergy of $35 million from the Melinta acquisition during Q4 2025 and is focused on integrating operations for long-term sustainable growth [5] - CorMedix is actively engaging with multiple Medicare Advantage providers and new potential customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [8] - The company has announced a share repurchase program, indicating confidence in its financial flexibility and growth potential [21] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and anticipates 2026 to be transitional, setting the stage for long-term growth in 2027 and beyond [21] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price for DefenCath [7] - Management is confident in the outlook for 2026 and the path to future growth and sustained profitability [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [9] - The Nutriguard clinical study for DefenCath is approximately 30% enrolled, with completion anticipated in early 2027 [14] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and 2027 [23] Question: Clinical significance of REZZAYO phase III data - Management highlighted the importance of various success metrics in the data, which will guide marketing strategies and discussions with payers [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding additional customers [33][41]

Financial Data and Key Metrics Changes - For the full year of 2025, revenue was approximately $237,000, an increase from $96,000 in 2024 [7] - Net loss was approximately $20.3 million or a loss of $0.16 per share, an improvement from $22.5 million or a loss of $0.19 per share in 2024 [8] - R&D investment was approximately $11.5 million compared to $16.8 million in the prior year [8] - G&A expense was approximately $9.5 million compared to $6.4 million in the prior year [8] - Year-end cash position was approximately $69 million, roughly double the $34.9 million at the end of the third quarter [8] Business Line Data and Key Metrics Changes - Customer programs deepened in 2025, with stage three engagements primarily involving wafer-level tape-outs, chip processing, and testing [9] - Three programs advanced to stage three, with a fourth Fortune Global 500 customer added in 2026 [6] - Approximately 15 additional engagements are progressing through stages one and two [6] Market Data and Key Metrics Changes - The market for Ethernet optical transceivers of 100G and above and CPO reached approximately $16.5 billion in revenue in 2025, projected to reach approximately $26 billion in 2026, corresponding to a 60% growth rate [16] - AI clusters are expected to consume roughly 80% of Ethernet transceivers and CPO through 2031 [16] - 1.6 terabit per second transceivers revenue is expected to reach $1 billion in 2026, with 3.2 terabits per second optics volume production beginning in 2028 [16] Company Strategy and Development Direction - The company is focused on building durable, repeatable revenue streams supported by qualification and design wins, rather than pursuing short-term revenue [11] - The strategy is to enhance silicon photonics rather than compete against it, allowing for higher bandwidth with lower power per bit [12] - 2026 priorities include advancing stage three programs towards qualification milestones, converting technical engagements into structured commercial agreements, and broadening the electro-optic polymer-ready silicon foundry ecosystem [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the AI opportunity and commitment to building long-term shareholder value [19] - The company is preparing for scalable integration and operational discipline, emphasizing the importance of technology and operational controls for durable companies [18] - The timeline for volume production and licensing revenues is not anticipated until 2027 at the earliest, with a disciplined approach to qualification cycles [11] Other Important Information - The company completed a public offering in December 2025, raising approximately $32.8 million in net proceeds [8] - The focus is on supporting customers inside foundry environments rather than isolated R&D settings [9] - The company has agreements in place with four major foundries, with wafer runs either underway or scheduled for the first half of 2026 [15] Q&A Session Summary Question: What specific milestones remain to complete the technology transfer, and is transfer dependent on PIC completion with stage three partners? - Management indicated that they intend to proceed with back-end of line process and capacity expansion in Denver to support prototyping and final product qualification [22] Question: Are you able to provide guidance on production volume requirements for 2026? - Management stated they are planning for success and have made aggressive assumptions related to their ability to win share in 2027 and 2028 [23] Question: Can shareholders expect to see an EOP modulator-based pluggable transceiver prototype completed this year? - Management noted that customers are working diligently on silicon photonic PICs, and updates will be provided throughout 2026 [24] Question: When a product is finalized, do we expect to see joint press releases? - Management mentioned that visibility will be provided through quarterly financial and business update calls, but customer decisions will dictate press releases [25] Question: What specific performance metrics will be validated for the mid-2026 device characterization? - Management confirmed that the tapeout is a significant milestone that will validate key design and performance parameters for modulators [26]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, compared to $49.8 million for the full year, with a significant portion coming from licensing revenue of $4.3 million from Novo Nordisk [23] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024, and full year expenses dropped to $61.1 million from $84.5 million [24] - Selling, general and administrative expenses for Q4 2025 were $8.8 million, down from $32.3 million in Q4 2024, with full year expenses decreasing to $37.3 million from $143.1 million [24][25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [25] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, pilavapadin for chronic pain, and LX9851 for obesity [4][5] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission expected in 2026 [6][12] - Pilavapadin is phase 3-ready for diabetic peripheral neuropathic pain (DPNP), with a successful end of Phase II meeting with the FDA [20][21] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [9][11] - There are approximately 1 million patients with type 1 diabetes in the U.S., highlighting the market potential for Zynquista if approved [17][18] Company Strategy and Development Direction - The company aims to maintain operational discipline and improve its financial position to support core programs [7] - A partnership strategy is in place to support existing collaborations and explore new partnerships, particularly for pilavapadin [6][19] - The company is focused on driving multiple pivotal milestones in 2026 across its core programs [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress and the potential for significant value creation from upcoming catalysts [30] - The company is optimistic about completing enrollment in the SONATA-HCM trial and anticipates data readouts in 2027 [66][67] Other Important Information - The company has reduced total debt by approximately $46.3 million in 2025, primarily using proceeds from the Novo Nordisk upfront payment [28] - Operating expenses were reduced by $39 million in Q4 2025 compared to Q4 2024, reflecting strategic repositioning [28] Q&A Session Summary Question: What is the status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is tracking data that gives confidence in submission and approval timelines [33][34] Question: How have the Phase 2 results impacted partnership discussions for pilavapadin? - Discussions with potential partners are ongoing, and the end of Phase 2 meeting has provided confidence around moving into Phase 3 [39][40] Question: What are Novo Nordisk's plans for LX9851? - The company believes Novo is exploring various options for LX9851, including its use in combination therapies for obesity management [41][42] Question: Is there flexibility to start the pilavapadin study without a partner? - The company is focused on cardiometabolic opportunities and is preparing for the Phase 3 program while engaging in partnership discussions [48][49] Question: What changes will be made to the Phase 3 design of pilavapadin? - The company plans to expand enrollment criteria and improve patient training on pain score assessments to mitigate placebo response [70][73]

Financial Data and Key Metrics Changes - Fourth quarter sales were essentially flat year-over-year, but excluding the impact from exiting low-margin products, sales would have increased by 3% [4][16] - Adjusted operating margins expanded by 230 basis points, and adjusted EPS improved by 63% year-over-year [5][16] - Full year 2025 net sales were $825.7 million, down 1.3% year-over-year, with adjusted gross margin increasing by 30 basis points to 33.7% [16][18] - Free cash flow improved by 23% to $67.2 million, and net debt was reduced by $44.2 million, resulting in a net leverage ratio of 2.4 [7][18] Business Line Data and Key Metrics Changes - Material Handling net sales decreased by $0.4 million, but excluding the impact of idling rotational molding facilities, sales increased by 3.4% [17] - Distribution net sales increased by 0.9%, with adjusted EBITDA margin improving by 160 basis points [17] - Adjusted EBITDA margin for Material Handling was 25.6%, expanding by 290 basis points due to focused transformation savings [17] Market Data and Key Metrics Changes - Industrial market is expected to see moderate growth, with recovery in manufacturing capital expenditures and increased demand for military products [22][34] - Infrastructure spending remains strong, particularly for large construction and utility projects, with a record backlog for matting products [22] - Consumer market is anticipated to be stable, with some fluctuations due to weather-related demand [23] Company Strategy and Development Direction - The company is focusing on a transformation program aimed at improving profitability and operational efficiency, with a disciplined capital allocation framework [8][10] - Strategic priorities for 2026 include focusing on core markets, instilling operational excellence, and maximizing profitable growth through disciplined investments [12][14] - The decision to sell Myers Tire Supply is part of a strategy to streamline operations and focus on high-margin growth platforms [4][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging demand environment and achieve long-term strategic goals [6][7] - The outlook for 2026 includes expectations for moderate growth in industrial markets and stable conditions in consumer markets, with ongoing monitoring of geopolitical risks [21][22] - Management emphasized the importance of continuous improvement and adapting to market conditions, particularly regarding material costs [41] Other Important Information - The company returned $23 million to shareholders in 2025 through dividends and share repurchases, highlighting its commitment to shareholder value [19] - The capital allocation framework balances growth investments with returning cash to shareholders, with plans to increase CapEx to approximately 3% of sales in 2026 [19][20] Q&A Session Summary Question: Broader end market sentiment and breakdown of industrial subcategories - Management noted that industrial production has been strong, with specific product lines like Akro-Mils and Buckhorn tracking closely with market strength [30][31] Question: Demand from U.S. military and NATO orders - Management confirmed sales to both U.S. military and NATO, with expectations for growth driven by geopolitical factors and military needs [35][36] Question: Material handling margins and sustainability of new levels - Management indicated that the strong performance in material handling margins is expected to continue, supported by ongoing transformation efforts and cost reductions [40][41] Question: Incremental cost reductions for 2026 - Management acknowledged that some cost savings will carry into 2026, but specific targets are not yet defined due to pending business changes [44][45]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, down from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [10][11] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% of revenue) in the prior year [10][11] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [11][12] - Net loss for 2025 was $23.9 million ($2.10 per share), improved from a net loss of $30.2 million ($3.03 per share) in 2024 [12][13] - Adjusted EBITDA loss for 2025 was $20.3 million, compared to a loss of $14.8 million in 2024 [13] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE phase 3 study [10][11] - SG&A expenses totaled $3.6 million in Q4 2025, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [11] - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold [8][9] Market Data and Key Metrics Changes - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing the majority of Vericel's approximately 90 target accounts [9] - Recent data from the Israel Defense Forces indicated that NexoBrid was clinically applicable in 71% of war-related injuries, supporting its role in acute trauma care [9] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for the expanded facility [16] - MediWound has reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of Defense [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges while focusing on clinical milestones and commercial objectives [5] - The company anticipates a significant increase in revenues in the second half of 2026, driven by manufacturing capacity and BARDA revenue [83] Other Important Information - The company completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, strengthening its balance sheet [14][15] - The company is expanding its clinical program for EscharEx beyond venous leg ulcers to include diabetic foot ulcers and pressure ulcers, with studies expected to begin in the second half of 2026 [7][8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - Management indicated that the expanded manufacturing facility is operational, with regulatory approvals expected in late 2026, and demand is larger than current manufacturing capacity [19][20] Question: Can you discuss the pressure ulcer trial and its potential market size? - Management noted that pressure ulcers are considered a significant market opportunity, and a third-party market research project will help assess the size of the addressable market [27][28] Question: What is the status of BARDA and DoD support for revenue guidance? - Management confirmed that revenue guidance includes potential contributions from BARDA and the DoD, with ongoing discussions expected to resume following the normalization of federal operations [33][34] Question: How is the supply chain for clinical studies being managed amid geopolitical tensions? - Management assured that there is sufficient EscharEx supply to support the trial for at least six months, with no anticipated supply chain issues impacting the clinical study [46] Question: What is the expected impact of the interim analysis on the VALUE trial timeline? - Management stated that the interim analysis will be conducted after 65% enrollment, with potential adjustments to sample size if necessary, which could impact the timeline [44]

Financial Data and Key Metrics Changes - Net sales for Q4 were approximately $5.4 billion, an increase of 5.5% year-over-year [18] - Total comparable club sales, including gasoline, rose 1.6%, while merchandise comparable sales increased by 2.6% [18] - Adjusted EPS for Q4 was $0.96, reflecting a 3.2% increase year-over-year, with full fiscal year adjusted EPS reaching $4.40 [22][24] Business Line Data and Key Metrics Changes - Grocery, perishables, and sundries business saw comparable sales growth of 2.3%, driven by strong performance in non-alcoholic beverages, candy, and snacks [19] - General merchandise and services division comp increased by 4.3%, supported by strength in consumer electronics and apparel [19] - Membership fee income rose by 10.9% to approximately $129.8 million, aided by healthy acquisition and retention trends [20] Market Data and Key Metrics Changes - The company opened 14 new clubs in fiscal 2025, the highest number in a single year, contributing to membership growth of over 500,000 members [4][5] - Digital sales penetration reached 16%, with digitally enabled sales growing by 31% [11][12] - The company ended the year with over 8 million members, achieving a 90% tenured renewal rate [10] Company Strategy and Development Direction - The company aims to continue expanding its footprint with plans to open 25-30 new clubs over 2025 and 2026, reflecting confidence in its business model [16][24] - Investments in digital capabilities and supply chain improvements are prioritized to enhance member experience and operational efficiency [12][24] - The focus remains on delivering value, convenience, and quality to members, particularly in a cautious consumer environment [4][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic environment marked by cautious consumer behavior and macroeconomic volatility [4] - The company anticipates comparable sales growth of 2%-3% for fiscal 2026, with adjusted EPS guidance of $4.40-$4.60 [23][24] - Management highlighted the importance of maintaining a strong pricing position to deliver value to members [13][25] Other Important Information - The company achieved record full-year earnings per share, reflecting disciplined execution across the business [5] - Inventory levels increased by 3.1% year-over-year, with in-stock levels improving significantly [22] - The company repurchased approximately 1.3 million shares for $117.7 million during the quarter, indicating confidence in long-term business strength [23] Q&A Session Summary Question: Merchandise margins down 50 basis points - Management noted that the primary contributor to margin performance was the mix of business, particularly a shift towards lower-margin general merchandise categories [32][34] Question: Growth potential in Texas and nationwide - Management expressed optimism about growth in Texas, citing strong engagement and membership sign-ups ahead of new club openings [40][41] Question: Impact of Winter Storm Fern on sales - Management indicated that Winter Storm Fern had a slight positive impact on the quarter, with a significant buildup in sales prior to the storm [47][48] Question: Membership fee income increase - Management confirmed that part of the membership fee income growth was due to a fee increase, alongside strong acquisition and retention trends [58][59] Question: Digital growth and fulfillment capabilities - Management stated that the company is well-positioned to handle increased digital fulfillment, with ongoing investments to support growth [66][67] Question: Guidance on merchandise margins for 2026 - Management did not provide specific guidance on merchandise margins but indicated that they would continue to manage pricing investments to enhance long-term value [74][75]

Financial Data and Key Metrics Changes - Invivyd's net revenues for Q4 2025 increased by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [26] - The company ended the year with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [26] Business Line Data and Key Metrics Changes - The commercial work with PEMGARDA showed growth in Q4, establishing a foundation for broader commercialization of VYD2311 if approved [5] - The company reported a high reorder rate of 77% for PEMGARDA, indicating strong ongoing demand [24] Market Data and Key Metrics Changes - There is a growing recognition of monoclonal antibodies in the medical community, with leading organizations recommending their use for high-risk patients [22] - The company has secured over 15,000 contracted GPO sites, significantly expanding its commercial footprint [24] Company Strategy and Development Direction - Invivyd aims to redefine COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [25] - The company is focusing on expanding its portfolio to include treatments for other infectious diseases, such as RSV and measles, indicating a broader strategic vision [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [18] - The company is optimistic about the speed of study recruitment and the potential for robust assessment of VYD2311's effectiveness [20] Other Important Information - Invivyd is conducting its third randomized placebo-controlled trial for a COVID monoclonal antibody, which is designed to adapt to virus evolution [14] - The company is exploring the use of monoclonal antibodies for long COVID and post-vaccination syndrome, highlighting its commitment to addressing unmet medical needs [7] Q&A Session Summary Question: Can you elaborate on the potential trial resizing decision in the DECLARATION program? - Management indicated that the resizing decision would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [29][30] Question: Are secondary endpoints being collected in the trial? - Management confirmed that various interactions, including healthcare utilization, would be recorded, but cautioned against expecting meaningful powering of low-frequency clinical events [34][35] Question: What is the envisioned use case for the measles antibody program? - Management highlighted potential use cases for outbreak prophylaxis and pediatric bridge therapy, emphasizing the antibody's design to address specific medical needs [37][41] Question: How is the DECLARATION study configured to target areas with high COVID rates? - Management explained that the study sites are strategically located in areas with community COVID attack rates, utilizing various data sources to inform site selection [46][48] Question: What is the approach to monitoring myocarditis in the study? - Management stated that the monitoring would primarily focus on clinical myocarditis events, with the possibility of further exploration if such events occur [50][51] Question: How does Invivyd plan to compete in the RSV antibody market? - Management expressed confidence in their antibody's properties and the potential to address evolutionary drift, positioning it as a competitive option in the RSV market [56][58]